StemCell Institute (TSE:7096) Total Operating Expense: 円1,510 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7096 StemCell Institute TSE:7096
69 GF Score
Price 円768.00
GF Value 円1,814.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is StemCell Institute Total Operating Expense?

StemCell Institute TSE:7096 +0.39% 69 Total Operating Expense is 円1,510 Mil as of Mar. 2026. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,814.87 (Possible Value Trap). The stock has 6 warning signs investors should review.

StemCell Institute's Total Operating Expense for the six months ended in Mar. 2026 was 円769 Mil. StemCell Institute's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,510 Mil.

StemCell Institute Total Operating Expense Related Terms

StemCell Institute Total Operating Expense Historical Data

* Premium members only.

The historical data trend for StemCell Institute's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute Total Operating Expense Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 884.31 1,038.28 1,162.12 1,273.58 1,509.53

StemCell Institute Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 595.31 623.48 650.10 741.00 768.53
TSE:7096
69GF Score
StemCell Institute TSE:7096
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円1,510 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円1,510 Mil mean?
StemCell Institute (TSE:7096) has a Total Operating Expense of 円1,510 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on StemCell Institute and its competitors.
Is StemCell Institute's Total Operating Expense too high?
StemCell Institute's current Total Operating Expense is 円1,510 Mil. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Total Operating Expense compare to VRTX and REGN?
StemCell Institute's Total Operating Expense of 円1,510 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on StemCell Institute and its competitors. StemCell Institute's current Total Operating Expense is 円1,510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,814.87, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current Total Operating Expense is 円1,510 Mil. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Total Operating Expense is 円1,510 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,814.87. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • Total Operating Expense: 円1,510 Mil
  • GF Value™: 円1,814.87 vs. price of 円768.00 (57.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score

Get the complete analysis for TSE:7096

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円768.00
Price
円1,814.87
GF Value